ESTEVE to acquire medicine to treat medullary thyroid cancer

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ESTEVE-Sanofi

More Like This

PR Newswire associated0

ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence

Capivasertib approved to treat patients with advanced breast cancer

PR Newswire associated0

ESTEVE'S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

PR Newswire associated0

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

PR Newswire associated0

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer